.Pharmacolibrary.Drugs.ATC.L.L01FX21 .Pharmacolibrary.Drugs.ATC.L.L01FX21| name: | Naxitamab | |
| ATC code: | L01FX21 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 3 | mg |
| volume of distribution: | 0.07 | L |
| clearance: | 0.013 | L/h/kg |
| other parameters in model implementation | ||
Naxitamab is a humanized monoclonal antibody that targets the disialoganglioside GD2. It is indicated for the treatment of relapsed or refractory high-risk neuroblastoma in pediatric and adult patients and is approved by the FDA for this use. Its main therapeutic activity comes from immune-mediated killing of GD2-expressing tumor cells.
Estimated pharmacokinetic parameters for intravenous administration in pediatric patients with high-risk neuroblastoma, as no direct published PK study was found.